An early failure in #PancreaticCancer - RIP1 kinase inhibitor as a modulator of the immune suppressive microenvironment.
Very promising preclinical data in last year:
cell.com/cancer-cell/fu
But the toxicities were overwhelming. Back to the drawing board.
Quote Tweet
The drug had been designed to work in tandem with checkpoint-inhibiting medicines such as Keytruda and Opdivo in the hopes of empowering the immune system to launch a more aggressive attack against tumors: fiercebiotech.com/biotech/glaxos
